Superstring Capital's Definium Therapeutics Investment: Q4 2025 Position - News and Statistics

NodeGuardian · 2026-04-08T01:32:49+00:00

Superstring Capital Management invested $5.69 million in Definium Therapeutics by acquiring 425,202 shares, making up 3.05% of its U.S. equity assets. This investment highlights Superstring's focus on biotechnology, as Definium approaches key trial results in 2026.

NodeGuardian

2026-04-08 01:32:49

Abstract generation in progress

Superstring Capital Management has acquired a new stake in Definium Therapeutics, valued at $5.69 million, by purchasing 425,202 shares in Q4 2025. This investment represents 3.05% of Superstring Capital’s U.S. equity assets, continuing its focus on clinical-stage biotechnology companies. Definium Therapeutics, a biopharmaceutical firm specializing in brain health disorders, is expected to release results from several late-stage clinical trials throughout 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes